Epstein-Barr Virus and Cancer Risks

Cancer Clinical Trial

— EBVCR  

Official title:

Prospective Cohort Study on Epstein-Barr Virus Antibody and Cancer Risks

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06203314
• Other study ID #: EBV-PRO-001
• Status: Recruiting
• Start date: August 1, 2008
• Est. completion date: December 31, 2030

Study information

• Verified date: January 2024
• Source: Sun Yat-sen University
• Contact: Wei-Hua Jia
• Phone: 86+020-87342327
• Email: jiawh[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this prospective cohort study is to investigate the associations between Epstein-Barr Virus (EBV) antibody levels and the risk of overall and site-specific cancer types in Southern China. The main questions it aims to answer are: Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?

Description:

Growing molecular evidence suggests the involvement of EBV in various cancers, however, comprehensive epidemiological evidence is still lacking. In this study, researchers conducted a population-based prospective cohort study to investigate the associations between EBV antibodies and the risk of overall and site-specific cancer types in Southern China. All the participants underwent EBV antibody tests at enrollment and were subsequently followed up annually for cancer incidence, vital status, and immigration status. The primary objective of this study was to provide prospective evidence for the role of EBV in multiple cancers, shedding light on the etiology of a broad range of common EBV-associated cancers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100000
• Est. completion date: December 31, 2030
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 69 Years

Eligibility

Inclusion Criteria:

• Subject residents in Zhongshan or Wuzhou City;
• Subject has no medical record of prevalent cancer;
• Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study's follow-up procedures.

Exclusion Criteria:

• Subject has heavy cardiovascular, liver, or kidney disease;
• Subject has prevalent cancer.

Related Conditions & MeSH terms

• Cancer
• Epstein-Barr Virus Infections

Intervention

Other:
• Diagnostic test: EBV antibody tests
Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.

Locations

Country	Name	City	State
China	Wuzhou Red Cross Hospital	Wuzhou	Guangxi
China	Zhongshan People's Hospital	Zhongshan	Guangdong

Sponsors (3)

Lead Sponsor	Collaborator
Sun Yat-sen University	Wuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cancer incidence	The primary outcome of the study was the diagnosis of any type of cancer. The cancer type for each participant was defined as their initial and primary cancer diagnosis.	10 years
Secondary	All-cause mortality	The participants were followed up annually for cancer incidence, vital status and immigration status through the Cancer Registry, Death Registry, and Population Registry of local regions.	10 years